Johns Hopkins ABX Guide
Rifapentine
INDICATIONS
FDA
FDA
- Treatment of active tuberculosis (in combination with other anti-tubercular drugs) in patients ≥ 12 years of age
- Treatment of latent TB in combination with isoniazid in patients ≥ 2 years of age at high risk of progression to TB disease.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: August 29, 2019
Citation
Avdic, Edina. "Rifapentine." Johns Hopkins ABX Guide, The Johns Hopkins University, 2019. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540484/all/Rifapentine.
Avdic E. Rifapentine. Johns Hopkins ABX Guide. The Johns Hopkins University; 2019. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540484/all/Rifapentine. Accessed December 3, 2023.
Avdic, E. (2019). Rifapentine. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540484/all/Rifapentine
Avdic E. Rifapentine [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2019. [cited 2023 December 03]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540484/all/Rifapentine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rifapentine
ID - 540484
A1 - Avdic,Edina,Pharm.D.
Y1 - 2019/08/29/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540484/all/Rifapentine
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
